A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with B-cell Non-Hodgkin Lymphoma

*  Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent
*  Diagnosis of mature aggressive large B cell non-Hodgkin lymphoma or follicular lymphoma
*  Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
*  Must have relapsed or refractory disease with the following indications for each histologic subtype: Mature aggressive large B cell non-Hodgkin lymphoma (NHL) and follicular lymphoma Grade 3b: Participants must have \>= 2 lines of systemic therapy, or \>= 1 line of systemic therapy for participants who are ineligible for autologous stem cell transplant; Follicular lymphoma Grade 1-3a and marginal zone lymphoma: Participants must have \>= 2 prior lines of anti-neoplastic systemic therapy. Participants also must have prior exposure to an anti-CD20 monoclonal antibody
*  Measurable disease as defined by Lugano 2014 classification
*  Eastern cooperative oncology group (ECOG) performance status of either 0 or 1 Exclusion Criteria
*  Diagnosis of Human herpes virus (HHV) 8-positive diffuse large B Cell lymphoma (DLBCL)
*  Prior allogeneic hematopoietic stem cell transplantation (HSCT)
*  Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion
*  Uncontrolled active infections
*  History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis \[DVT\])
*  History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening
*  History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or neurodegenerative disorder
*  Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
*  Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)